EGFR Resisters/LUNGevity Research Award Program for EGFR-positive Lung Cancer

IMPORTANT NOTES TO READ BEFORE PROCEEDING:

EGFR Resisters is partnering with LUNGevity Foundation (“LUNGevity”) to issue an RFA specific to the study of EGFR-positive lung cancer.

LUNGevity Foundation advises applicants to read the entire RFA, including eligibility requirements and other terms and conditions, before starting an application.

An applicant who is deemed ineligible for this award and/or does not follow the instructions for preparing the application will be disqualified and the application not reviewed.

The EGFR Resisters/LUNGevity Lung Cancer Research Award Program for EGFR-positive Lung Cancer uses a two-step application process. An applicant must first submit a letter of intent (LOI). Only a subset of applicants will be invited to submit a full application after the LOIs are reviewed.

Detailed instructions for submitting an EGFR-positive Lung Cancer Research Award Program application, including critical dates, begin on page 10.

This award application process will be managed through proposalCENTRAL.

EGFR RESISTERS

EGFR Resisters is a grassroots community of close to 2,000 EGFR-positive lung cancer patients and caregivers from 70+ countries, dedicated exclusively to improving outcomes for people with EGFR-positive lung cancer by changing EGFR-positive lung cancer into a manageable, chronic disease. The group uses the strength of its collaborations to drive important research questions and fund novel research and clinical trials. For more information about EGFR Resisters, please visit www.egfrcancer.org.

LUNGEVITY FOUNDATION

LUNGevity Foundation is a 501(c)(3) philanthropy specifically focused on funding research for the early detection and effective treatment of lung cancer. LUNGevity’s mission is to improve mortality rates of lung cancer patients through the development of protocols and tools for early detection of lung cancer, early intervention in the disease progression, and treatments, including targeted therapy and immunotherapy. LUNGevity focuses on translational science. For more information about LUNGevity Foundation, please visit www.LUNGevity.org.

EGFR-POSITIVE LUNG CANCER RESEARCH AWARD PROGRAM FUNDING OPPORTUNITY DESCRIPTION

Goal of the program:

To fund high-impact research that seeks to transform the future for patients diagnosed with EGFR-positive lung cancer by changing EGFR-positive lung cancer into a chronic or curable condition.

Overview:

EGFR Resisters is partnering with LUNGevity Foundation to support EGFR-positive non-small cell lung cancer research. EGFR Resisters will leverage LUNGevity’s scientific review process as well as fund its
research through the Foundation. This research will address the critical unanswered questions in the EGFR space. This award program is separate from, and in addition to, LUNGevity’s Career Development, Early Detection, and Targeted Therapeutics award programs. It aligns well with the Foundation’s mission of funding high-impact science.

With this award, EGFR-positive patients are expediting the research process themselves both by fund-raising and crowdsourcing. In addition to fundraising, members of EGFR Resisters are also committed to facilitating research by offering up their available histories, opinions, tissues, bodily fluids (blood, urine, etc.), and/or any other specimens or information about their condition to the funded investigators.

The recipient(s) of the award will be announced in January 2021. The award(s) may be for a maximum of $100,000 per year for two years, for a maximum award of $200,000.

EGFR-positive Lung Cancer Research Award Program requirements

The research project(s) that will be funded is (are) expected to have a direct impact on the outcomes of patients with advanced EGFR-positive lung cancer, but innovative proposals that address other unmet needs in the EGFR-positive lung cancer space are also invited for submission. Please note that we are not accepting psychosocial research proposals as part of this RFA. Applicants are encouraged to propose projects that utilize the resources of the members of EGFR Resisters.

Successful applicants are required during the duration of the award term to share their research progress with the members of EGFR Resisters and the LUNGevity team (Scientific Advisory Board, other reviewers, and other awardees) every six months virtually and annually at the LUNGevity science meeting.

**Scientific scope:**

The goal of the award is to fund impactful proposals in the EGFR-positive lung cancer space. Potential areas of exploration include, but are not limited to, the following types of projects:

- Novel treatment approaches, either TKI or non-TKI, including methods for optimizing first-line EGFR TKI therapy
- Novel combination-treatment approaches, based on rational hypotheses
- Novel treatment options after progression on osimertinib, including histological transformation
- Evaluation of novel immunotherapy approaches
- Identification of biomarkers, including cfDNA approaches, that predict both sensitivity to specific therapies and timing of relapse on therapy
- Novel applications of liquid and tissue biopsies (and/or other methodologies) to improve understanding of TKI resistance and/or tailor therapy
- Effective treatment strategies for brain metastases and leptomeningeal disease

Projects are to include at least one aim that is translational and must be directly related to improvement of patient outcomes and/or lead to a clinical trial.

Final selection of the project(s) to be funded will be contingent on scientific review and availability of funds.

**Award eligibility:**

If an applicant does not currently meet an eligibility requirement, but either will meet it soon or has special circumstances that prevent it from being met, the applicant must let us know at the
time the LOI is submitted. A page with the information should be attached to the back of the biosketch.

Education and Experience: This award program is open to all faculty members. At the time of the award term, an applicant (who must be a principal investigator for the proposed research) must 1) hold a doctoral degree, 2) have a faculty appointment with a university-based academic institution or a research institution that is not formally associated with a university, and 3) have completed a postdoctoral training fellowship. An applicant may be at any level of research experience. **However, if an applicant is within five years of their faculty appointment, a mentor must be identified. This mentor must vouch for the successful completion of the proposed project or be able to explain the applicant's special circumstances that mean a mentor is not needed.**

An applicant must be an independent, self-directed researcher for whom their institution must provide space and other resources customary for independent investigators. The application must convey the commitment of the institution to the applicant and the proposed research activities.

Current LUNGevity award: An applicant with a LUNGevity award that would be concurrent with a 2021 EGFR-positive Lung Cancer Research Award is not precluded from applying.

Geographical Restriction: The Award Program is open to applications that include an international collaborator. At the time of application, an international collaborator (who is not employed by a U.S. institution and either is or is not a United States citizen) must name a co-investigator who 1) is employed by a U.S. institution and stays so throughout the duration of the award term and 2) is either a U.S. citizen or a foreign national with one of the immigration statuses outlined in the following paragraph. Disbursement of funds for the award must be made through a U.S. institution to allow timely commencement of project.

Applicants are not required to be U.S. citizens or to be employed by a U.S. institution. **At the time of application, if an applicant is employed by a U.S. institution, they must be a United States citizen or a foreign national holding one of the following visa immigration statuses: permanent resident (Green Card), exchange visitor (J-1), temporary worker in a specialty occupation (H-1, H-1B), Canadian or Mexican citizen engaging in professional activities (TC or TN), or temporary worker with extraordinary abilities in the sciences (O-1). This applicant/awardee must be employed by a U.S. institution throughout the duration of the award term.**

**Award information:**

Award Structure and Allocation:

An awardee may receive **up to $200,000 over two years.** No more than 25% of the requested budget may be used for an investigator's salary and/or fringe benefits and no more than 10% of the total award budget may be used for overhead/indirect costs.

Award funds may be used for the salary and fringe benefit costs of personnel other than the applicant. Fringe benefit costs may only be expended upon the stipulation that they cannot be obtained from another source.

Allowable costs for clinical trials include: expenses related to subject recruitment (such as participation incentives, subject remuneration, phlebotomy charges, etc.), clinical laboratory analyses of human subjects or their samples (such as clinical laboratory assays, imaging charges, etc.), and correlative studies. The award may be used to assist with operational costs, **However, drug costs will not be covered.** The applicant must provide a letter of commitment of support for the project from the pharmaceutical partner, including that they will provide the drug.

**Duration:** The EGFR-positive Lung Cancer Research Award is subject to six-month reviews and may be
granted for up to two years. The second year of support is based on demonstrating satisfactory progress in the first year.

Factors considered in evaluating applications:

Some of the factors considered when reviewing applications include:

- **Innovation** – Does the project address a previously uninvestigated area of EGFR-positive lung cancer?
- **Scientific merit and feasibility of the research plan**, including partnerships
- **Impact** – How will the research findings from the project move to the clinic within 1-2 years and impact patients? What plans does/do the applicant(s) have for the clinical application of the findings of the project?
- **Study design and its burden on patient participation**, i.e., how difficult is it for patients to participate in the proposed study?
- **Research environment** – Does the applicant have access to institutional resources required for the successful completion of the proposed project?
- **Appropriateness of the requested budget** to complete the proposed research project/Other sources of funding, including potential overlap with proposed project

OTHER TERMS AND CONDITIONS:

Following are the other terms and conditions that apply to the EGFR-positive Lung Cancer Research Award:

**Animal Use**

The EGFR-positive Lung Cancer Research Award Program allows animal use in biomedical research only when no other means of obtaining scientifically sound, valid, and useful results are available. Applicants must ensure that only the minimum number of appropriate animals required to obtain and validate results shall be used. In cases requiring the death of an animal, only the most appropriate and humane form of euthanasia shall be used consistent with the purpose of the research.

Whenever animal use is a part of the EGFR Resisters/LUNGevity-funded research project, applicants must provide EGFR Resisters/LUNGevity with institutional endorsements that the research facility, its research, and its employees adhere to the appropriate animal welfare regulations in their country. In the U.S., these include:

- Animal Welfare Act
- USDA rules
- National Research Council *Guide for the Care and Use of Laboratory Animals*
- Public Health Service Policy on Humane Care and Use of Laboratory Animals

In addition, those applicants who are invited to submit a full application must include in their materials the following documents:

- Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accreditation.
- Institutional Animal Care and Use of Committee (IACUC) approval.

A project is not eligible for an award if the research proposal involves animals and the institution does not have accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care.
International (AAALAC), or does not hold a current Public Health Service (PHS) Animal Welfare Assurance, or does not have accreditation from the United States Department of Agriculture or does not have accreditation from the Institutional Animal Care and Use Committee (IACUC).

**Authorized Award Holders:**

The EGFR-positive Lung Cancer Research Awards are granted only to an individual; awards are not awarded to institutions. No award may be held by or transferred to another individual.

**Award Payment Schedule:**

EGFR Resisters/LUNGevity will issue the initial award payment no earlier than January 2021 but as soon as the agreement document is fully executed. Assuming award renewals, contingent on meeting milestones, EGFR Resisters/LUNGevity will issue the second payment following award renewal. The second payment will be made only after the awardee’s funding balance has decreased to $25,000 or less.

**Biohazards:**

Biohazards are broadly defined to be recombinant and/or infectious and tumor materials that may be deleterious to normal organisms upon controlled exposure. Research involving biohazards requires one paper copy of the appropriate institutional committee approval at the time a full application is submitted.

**Carryover of Funding:**

Carryover of funding into the second funding period requires prior approval by EGFR Resisters/LUNGevity. All requests must be in writing and received by EGFR Resisters/LUNGevity 60 days prior to the end of the first funding period. When making the request, the awardee must indicate the amount and from what budget-line and to what budget-line the carryover monies are being applied. In the case of supplies, all items must be itemized.

**Change in Budget:**

Requests for changes in budget require prior approval by EGFR Resisters/LUNGevity. All requests must be in writing and received by EGFR Resisters/LUNGevity 60 days prior to the end of the second six-month funding period. When requesting a change in budget, the awardee must indicate the amount and from what budget-line and to what budget-line the monies are being transferred. In the case of supplies, all items must be itemized.

**Change of Institution:**

Transfer of the EGFR Resisters/LUNGevity award from one institution to another requires prior approval by EGFR Resisters/LUNGevity. All requests must be in writing. All unexpended funds must be returned to EGFR Resisters/LUNGevity within 45 days of transfer approval. Once EGFR Resisters/LUNGevity receives the unexpended funds, they will be reissued to the new institution after an agreement document with the new institution has been fully executed.

**Equal Employment Opportunity:**

EGFR Resisters/LUNGevity awards will be awarded to individuals working in institutions identified as Equal Opportunity Employers.

**Equipment Purchase:**

None (0%) of the award budget may be used for the purchase of permanent equipment.
Equipment Repair & Service Contracts:

None (0%) of the award budget may be used for repair or service contract costs for institutional equipment.

Financial Reports:

An interim financial report is required at the same time as each of the interim progress reports. In addition, at the conclusion of the award period, EGFR Resisters/LUNGevity requires a complete financial disbursement report covering the entire award period. The disbursement report must reflect the award expenditures as approved by EGFR Resisters/LUNGevity. Any funds used for unauthorized expenditures or unexpended funds must be returned to EGFR Resisters/LUNGevity, with the disbursement report, within 60 days of the award termination date.

Human Subjects:

Whenever human participants are a part of the EGFR Resisters/LUNGevity-funded research project, the following documents must be received before any award monies are released:

• A copy of the Institutional Review Board (IRB) approval (or non-U.S. equivalent) and approved patient consent forms.

LUNGevity encourages applicants to submit their projects to the appropriate human subjects Institutional Review Board at the time of application.

• A copy of the appropriate institutional committee approval for research involving human adult stem cells or use of human fetal tissue.

If the proposed research project involves human subjects, the population sampled shall be inclusive of the general population of relevance to the scientific question posed, without restriction in regard to gender, race, age, and socioeconomic status. Proposals that intentionally restrict the population sampled must include a compelling scientific rationale for such design.

Malpractice Liability:

EGFR Resisters/LUNGevity will not assume responsibility for and the institution will indemnify and hold EGFR Resisters/LUNGevity harmless from any lawsuit, claim, judgment, damages, awards, or malpractice arising from research or investigations related to an award.

Other Funding:

EGFR Resisters/LUNGevity research funds will not be awarded to duplicate any work that is being supported by other funding agencies. Partial funding from a pharmaceutical company for a phase 1 trial is encouraged. Details about additional funding sought for the same project should be provided in the full application.

Overhead/Indirect Costs:

Overhead or indirect costs are permitted up to 10% of the award and are not incremental to the award. Duplication of indirect costs on subcontracts is not allowed.

Patent and Intellectual Property Policy:

Inventions and discoveries from research performed during the term of the EGFR Resisters/LUNGevity award will be subject to the current EGFR Resisters/LUNGevity patent policy as well as to the patent
policies of the institution where the work is performed. The LUNGevity policy is described in full on page 8.

Progress Reports:

Interim written progress reports are due every six months. Interim reports are the basis for the decision to award the next round of funding. A final written report is also required 45 days after the conclusion of the project. These reports are in addition to the progress presentations that will be made annually at the LUNGevity science meeting. Six-month virtual progress reviews will take place.

Project Support Expenditures:

No award shall be used for the purchase of furniture or computers, the construction or renovation of facilities, payment of honoraria or membership dues, payment for tuition, the purchase of textbooks or periodicals, or payment for secretarial support.

Public Access Policy:

All peer-reviewed articles supported in whole or in part by the EGFR Resisters/LUNGevity grant must be made available in the PubMed Central online archive. The EGFR Resisters/LUNGevity public access policy is described in full on page 9.

Publication Expenditures:

The maximum amount of funds expendable for publication costs is $1,000 per year. All publication costs must directly relate to the EGFR Resisters/LUNGevity project.

Publications and Conference Presentations:

All publications and/or presentations at scientific conferences and meetings based on research conducted from this award must include a citation of EGFR Resisters/LUNGevity as a supporting entity as follows: “This study was supported by a grant from EGFR Resisters/LUNGevity Foundation.” Reprints of abstracts, manuscripts, or other articles that reflect research done after award acceptance must be submitted to EGFR Resisters/LUNGevity.

Student Tuition:

EGFR Resisters/LUNGevity will not pay tuition for awardees or any key personnel.

Supply Purchases:

Upon conclusion of the award, supplies purchased with award funds become the property of the institution at which the work was done.

Tobacco-Funded Research

EGFR Resisters/LUNGevity will not provide research or other funding to applicants who have received direct funding or funding from agencies of the tobacco industry.

Travel Expenditures:

The maximum amount of funds expendable for travel is $3,000 per year per investigator. These travel funds can only be used if the work related to this grant is being presented in poster/oral presentation/abstract form. Travel to LUNGevity meetings is paid directly by the Foundation and should not be included in the $3,000.
EGFR RESISTERS/LUNGEVITY FOUNDATION PATENT AND INTELLECTUAL PROPERTY POLICY

a. All inventions or intellectual property made with support in whole or in part by research or training grants or awards from LUNGEVITY must be reported at the earliest practical time to the Research and Program Services Division. The grantee institution or individual awardee agrees to notify LUNGEVITY immediately of the decision to apply for letters patent or other legal protection for intellectual property, and to consider seriously and in good faith any comments or objections LUNGEVITY may have concerning such applications. LUNGEVITY agrees to keep all information confidential and to not release any information relating to such inventions, intellectual property or applications. All patenting expenses shall be borne by the grantee institution or individual awardee unless the intellectual property is ceded to LUNGEVITY (see paragraphs b and c).

b. Title to any invention or intellectual property shall reside in the grantee institution to the extent that such title is claimed by the institution under its patent policy or procedure and paragraphs c-e shall apply. If a grantee institution has no established patent policy or procedure for administering inventions or intellectual property, or if the institutional patent policy or procedure does not claim rights for the institution or individual inventor, then LUNGEVITY shall have the right to determine the disposition of invention or intellectual property rights and paragraphs c-d shall not apply.

c. No patent, patent application or other type of protection shall be abandoned without first notifying the Research and Program Services Division. At such time, the grantee institution and individual awardee shall give LUNGEVITY the opportunity to take title to the invention or other intellectual property.

d. The grantee institution shall agree that when it licenses any invention or intellectual property it will obligate the licensee as follows: The licensee agrees to exert its best efforts to commercialize or cause to be commercialized the invention or intellectual property as rapidly as practical, consistent with sound and reasonable business practices and judgment. In the event that the licensee has failed to commercialize the invention or intellectual property within the number of years determined to be reasonable for the invention or intellectual property, the grantee institution upon conferring with LUNGEVITY shall have the right to convert an exclusive license to a non-exclusive license or to terminate a non-exclusive license. If the licensee or grantee institution has an ongoing and active research, development, manufacturing, marketing or licensing program as appropriately directed toward the production and sale of the invention or intellectual property, the same would be deemed to be sufficient evidence that the licensee or grantee institution has commercialized the invention or intellectual property.

e. LUNGEVITY and EGFR Resisters reserve the right to public acknowledgment for inventions or intellectual property resulting from support by LUNGEVITY and EGFR Resisters; however, LUNGEVITY and EGFR Resisters name and logo may not be used in association with an invention or intellectual property without prior approval of LUNGEVITY and EGFR Resisters.
EGFR RESISTERS/LUNGEVITY FOUNDATION PUBLIC ACCESS POLICY

LUNGevity, in partnership with EGFR Resisters, is funding biomedical research in order to better understand the causes of lung cancer and to advance its prevention, diagnosis, and treatment. The main output of this research is new knowledge. To ensure this knowledge can be accessed, read, applied, and built upon in fulfillment of our goals, LUNGevity and the EGFR Resisters expect its researchers to disseminate their findings, including publishing in peer-reviewed journals.

In addition, it is a condition of this award that all peer-reviewed articles supported in whole or in part by its grants must be made available in the PubMed Central online archive. PubMed Central is a database of full-text biomedical journal articles available online without a fee, hosted by the National Library of Medicine in the National Institutes of Health. Once posted in PubMed Central, results of research become more accessible, prominent, and integrated, making it easier for scientists worldwide to pursue biomedical research. It also makes this information accessible to LUNGevity and the EGFR Resisters, as well as patients, clinicians, educators, students, and others.

Award recipients are required to deposit an electronic copy of their final peer-reviewed manuscripts in PubMed Central immediately upon acceptance for journal publication and take the steps necessary to link that manuscript to the appropriate EGFR Resisters/LUNGevity grant. The manuscript is to be made publicly available in PubMed Central no later than six months after the official date of journal publication. EGFR Resisters/LUNGevity award recipients must acknowledge EGFR Resisters/LUNGevity grant support in every article arising from such funding. The acknowledgment statement must include the applicable grant number. The award recipients must notify EGFR Resisters (by emailing egfrresisters@gmail.com) and LUNGevity Foundation (by emailing Margery Jacobson at mjacobson@LUNGevity.org) of any articles arising from such funding. This will enable the EGFR Resisters and LUNGevity to link the published outputs of research to the support that has been provided. LUNGevity and EGFR Resisters also encourage award recipients to publish in peer-reviewed open access journals with a policy of immediate availability of the published version without restriction and permits use of non-salary/stipend grant funds to pay associated publication fees.
Letter of Intent (LOI)

The letter of intent must include:

• A narrative that includes:
  1. **Rationale** for the project with details on how the project will impact clinical care of EGFR-positive lung cancer patients
  2. Planned **specific aims** (may be modified slightly in the full application)
  3. Brief statement of the **overall experimental approach**
  4. Brief statement describing the **clinical context** in which the therapeutic strategy will be used
  5. Brief statement of the **quantitative metrics/performance** that the approach should achieve to show clinical utility
  6. Pertinent **references**

The narrative should be typed in Arial 11-point type, single-spaced, with .5” margins. It should not exceed a total of **two pages**, excluding the references.

• An **NIH biosketch** of the applicant(s): principal investigator and co-principal investigators only. Note that “other support” should include the value of the support. Support should include past, current, and pending.

• If the proposed project is a clinical trial: a letter of support from the pharmaceutical partner that includes confirmation that the partners will provide the drug.

No budget information or other supporting materials should be included.

Templates and detailed instructions can be found at [https://proposalCENTRAL.com](https://proposalCENTRAL.com).

Applicants are required to electronically submit the LOI **by July 22, 2020 (11:59pm EST)**, via proposalCENTRAL: [https://proposalCENTRAL.com](https://proposalCENTRAL.com). Extensions will not be given. Once an LOI has been submitted electronically via proposalCENTRAL, it cannot be changed.

A sponsoring institution signature is not required.

Applicants will be notified by email no earlier than **August 28, 2020**, whether they may proceed with the full application. EGFR Resisters/LUNGevity will **not** provide results of the peer review process.

Full Application

Only invited applicants may prepare and submit a full application. Instructions for how to proceed will accompany the invitation.

Among other materials, the full application must include:

A narrative to include these eight components in this order:

  1. **Scientific Abstract** that would be appropriate for a reviewer of a peer-review journal
  2. **Lay Abstract** that explains your project completely in lay terms that will be clear to individuals who do not have a scientific background. Specific details on how the project will have a near-term impact on the clinical outcome of EGFR-positive lung cancer patients should be included.
3. **Background:** Present the ideas and reasoning behind the proposed research; include relevant literature citations. Describe previous experience most pertinent to this application.

4. **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.

5. **Specific Aims:** Concisely explain the project’s specific aims. Please include a description on whether and how you propose to include biospecimens from EGFR-positive lung cancer patients in your proposed experiments.

6. **Research Strategy:** Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for analysis. Address potential problem areas and present alternative methods and approaches.

   If proposing a clinical trial, please include a detailed sample size justification and any statistical analysis you propose to use. Also, clearly describe impact on patient participation (for example, number and frequency of blood draws and biopsies, number of clinical visits, etc.)

7. **Patient impact statement** – How will the research findings from the project move to the clinic within 1-2 years and impact patients? What plans does/do the applicant(s) have for the clinical application of the findings of the project?

8. **Other funds available to support the proposed project,** such as funds provided by drug companies for part of a clinical trial (as applicable)

9. **A few pertinent references**

The narrative should be typed in Arial 11-point type, single-spaced, with .5” margins. Clarity and brevity are highly desirable qualities in an application. The narrative should not exceed a total of 7 pages excluding the references.

- **NIH biosketches** of all PIs and Key Personnel. If a mentor is required, include the mentor’s biosketch. The biosketches should be limited to five pages each. Again, “Other Support” should include the value of the support. Support includes past, current, and pending.

- If the proposed project is a clinical trial: a letter of support from the pharmaceutical partner that includes confirmation that the partners will provide the drug.

- **Budget information** by six-month period, along with a justification

- If relevant, the following documents:
  - a copy of the documents listed on page 4-5 in the “Animal Use” section
  - a copy of the biohazard document named on page 5 in the “Biohazards” section

- Do not include reprints of your previous publications.

Templates and more detailed instructions for all of the above materials and any other materials that must be included can be found at https://proposalCENTRAL.com.

Applicants are required to electronically submit the **full application by October 16, 2020 (11:59pm EST),** via proposalCENTRAL: https://proposalCENTRAL.com. Extensions will not be given. Once a full application has been submitted electronically, it cannot be changed.

Applicants will be notified by email no earlier than **January 2021** whether they will receive an award. EGFR Resisters/LUNGevity will provide results of the peer review process for **full** applications.

Awardees will receive formal agreement documents at the time of or soon after award notification. These must be signed by both the awardee and an authorized representative of the sponsoring institution and then returned to LUNGevity before any funds will be released.
APPLICATION ASSISTANCE

For answers to questions regarding programs, eligibility, policies, terms and conditions, or instructions for the letter of intent or full application, please contact:

Margery Jacobson
Senior Research and Education Services Manager
mjacobson@LUNGevity.org
312-407-6109

For help with the proposalCENTRAL electronic application process, please contact:

Help Desk at proposalCENTRAL
pcsupport@altum.com
1-800-875-2562